Author + information
- Received March 20, 2009
- Revision received July 17, 2009
- Accepted July 25, 2009
- Published online October 1, 2009.
- Ian T. Meredith, MBBS, PhD⁎,⁎ (, )
- Stephen Worthley, MBBS†,
- Robert Whitbourn, MBBS‡,
- Darren L. Walters, MBBS§,
- Dougal McClean, MD∥,
- Mark Horrigan, MBBS¶,
- Jeffrey J. Popma, MD#,
- Donald E. Cutlip, MD⁎⁎,
- Ann DePaoli, DVM††,
- Manuela Negoita, MD††,
- Peter J. Fitzgerald, MD‡‡,
- RESOLUTE Investigators
- ↵⁎Reprint requests and correspondence:
Dr. Ian T. Meredith, Monash HEART and Monash University, Monash Medical Centre, 246 Clayton Road, Melbourne, Victoria, Australia
Objectives The RESOLUTE trial examined the safety and efficacy of a next-generation zotarolimus-eluting coronary stent, Resolute (Medtronic CardioVascular Inc., Santa Rosa, California).
Background Revascularization benefits associated with current drug-eluting stents are often diminished in the presence of complex coronary lesions and in certain patient cohorts. Resolute uses a new proprietary polymer coating that extends the duration of drug delivery to match the longer healing duration often experienced in more complex cases.
Methods The RESOLUTE trial was a prospective, nonrandomized, multicenter study of the Resolute stent in 139 patients with de novo coronary lesions with reference vessel diameters ≥2.5 and ≤3.5 mm and lesion length ≥14 and ≤27 mm. The primary end point was 9-month in-stent late lumen loss by quantitative coronary angiography. Secondary end points included major adverse cardiac events (MACE) at 30 days, 6, 9, and 12 months; acute device, lesion, and procedure success; and 9-month target vessel failure (TVF), target lesion revascularization (TLR), stent thrombosis, neointimal hyperplastic (NIH) volume, and percent NIH volume obstruction.
Results The 9-month in-stent late lumen loss was 0.22 ± 0.27 mm. Cumulative MACE were 4.3%, 4.3%, 7.2%, and 8.7% at 30 days, 6, 9, and 12 months, respectively. Acute lesion, procedure, and device success rates were 100.0%, 95.7%, and 99.3%, respectively. At 9 months, TLR was 0.0%, TVF was 6.5%, stent thrombosis was 0.0%, NIH volume was 6.55 ± 7.83 mm3, and percent NIH volume obstruction was 3.73 ± 4.05%.
Conclusions In this feasibility study, the Resolute stent demonstrated low in-stent late lumen loss, minimal neointimal hyperplastic ingrowth, low TLR, no stent thrombosis, and acceptable TVF and MACE. (The RESOLUTE Clinical Trial; NCT00248079)
This study was supported by Medtronic CardioVascular, Inc.
- Received March 20, 2009.
- Revision received July 17, 2009.
- Accepted July 25, 2009.
- American College of Cardiology Foundation